| Q98771514 | A Novel CD133- and EpCAM-Targeted Liposome With Redox-Responsive Properties Capable of Synergistically Eliminating Liver Cancer Stem Cells |
| Q92988450 | Current Status of Gene Therapy in Hepatocellular Carcinoma |
| Q91062934 | Liposomal delivery of CRISPR/Cas9 |
| Q38796320 | Modifying the tumor microenvironment using nanoparticle therapeutics |
| Q38812240 | Multifunctional platinum-based nanoparticles for biomedical applications |
| Q60049770 | Multifunctional selenium nanoparticles with Galangin-induced HepG2 cell apoptosis through p38 and AKT signalling pathway |
| Q28079367 | Nanomedicine strategies for sustained, controlled, and targeted treatment of cancer stem cells of the digestive system |
| Q38836010 | Organic nanoparticle systems for spatiotemporal control of multimodal chemotherapy |
| Q48258055 | Phosphatase-triggered cell-selective release of a Pt(iv)-backboned prodrug-like polymer for an improved therapeutic index |
| Q48280114 | Phospholipid-mimic oxaliplatin prodrug liposome for treatment of the metastatic triple negative breast cancer |
| Q55456898 | Ratiometric delivery of two therapeutic candidates with inherently dissimilar physicochemical property through pH-sensitive core-shell nanoparticles targeting the heterogeneous tumor cells of glioma. |
| Q36795642 | Silver Nanoparticles Induce HePG-2 Cells Apoptosis Through ROS-Mediated Signaling Pathways |
| Q64101613 | The Carcinogenic Role of the Notch Signaling Pathway in the Development of Hepatocellular Carcinoma |